Novo Nordisk and Life Edit Therapeutics Enter Gene Editing Collaboration in Rare and Cardiometabolic Diseases
By Lalit Mishra
Pharma Deals Review: Vol 2023 Issue 6 (Table of Contents)
Published: 8 Jun-2023
DOI: 10.3833/pdr.v2023.i6.2789 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Novo Nordisk has entered into a research and development collaboration with Life Edit Therapeutics to discover and develop next-generation gene editing therapies for rare genetic disorders as well as more prevalent cardiometabolic diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS